A number of other research analysts have also commented on INO. Royal Bank of Canada lowered Inovio Pharmaceuticals to a hold rating in a research note on Monday, April 6th. Stifel Nicolaus lowered Inovio Pharmaceuticals from a buy rating to a hold rating and increased their price objective for the stock from $19.00 to $24.00 in a research note on Friday, June 26th. Piper Sandler lowered Inovio Pharmaceuticals from an overweight rating to a neutral rating and set a $8.00 price objective for the company. in a research note on Friday, March 13th. Benchmark started coverage on Inovio Pharmaceuticals in a research note on Thursday, May 21st. They set a buy rating for the company. Finally, Cantor Fitzgerald increased their price objective on Inovio Pharmaceuticals from $13.00 to $17.00 and gave the stock an overweight rating in a research note on Wednesday, April 29th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $13.56.
Shares of NASDAQ INO opened at $26.95 on Friday. The business has a fifty day simple moving average of $15.68 and a 200 day simple moving average of $8.49. The company has a current ratio of 8.53, a quick ratio of 8.53 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of -22.65 and a beta of 1.39. Inovio Pharmaceuticals has a one year low of $1.91 and a one year high of $33.79.
In other news, Director David B. Weiner sold 2,404 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $11.84, for a total value of $28,463.36. Following the completion of the sale, the director now directly owns 827,219 shares in the company, valued at $9,794,272.96. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Laurent Humeau sold 19,467 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $14.70, for a total value of $286,164.90. Following the completion of the transaction, the insider now owns 63,433 shares in the company, valued at approximately $932,465.10. The disclosure for this sale can be found here. Company insiders own 4.00% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. US Bancorp DE boosted its holdings in Inovio Pharmaceuticals by 568.3% in the first quarter. US Bancorp DE now owns 6,683 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 5,683 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Inovio Pharmaceuticals by 19.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 8,259 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,318 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Inovio Pharmaceuticals by 79.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,666 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 4,266 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Inovio Pharmaceuticals by 10.2% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 10,250 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 950 shares during the last quarter. Finally, IHT Wealth Management LLC bought a new position in shares of Inovio Pharmaceuticals during the 1st quarter worth approximately $78,000. Institutional investors and hedge funds own 27.82% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Article: Market Capitalization in the Stock Market
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.